Event Timeline
| 05:00 PM - 05:06 PM CDT |
Speaker |
Results from the Global Phase 3 Trial (IB1001-303) Evaluating Levacetylleucine in Children and Adults with Ataxia-Telangiectasia
|
| 05:06 PM - 05:12 PM CDT |
Speaker |
Long-Acting IL-7 (NT-I7) as an Immune Reconstitution Strategy in PML: Immunological and Clinical Outcomes from a Pilot Study
|
| 05:12 PM - 05:18 PM CDT |
Speaker |
Association between Pre-Disease Plasma Neurofilament Light Polypeptide Biomarker and Amyotrophic Lateral Sclerosis Risk in the Danish Diet, Cancer and Health Study Cohort
|
| 05:18 PM - 05:24 PM CDT |
Speaker |
Long-Term Safety, Tolerability, and Efficacy of Atogepant for the Preventive Treatment of Migraine: Final Results from a Phase 3, Open-Label, 156-Week, Long-Term Safety Extension Study
|
| 05:24 PM - 05:30 PM CDT |
Speaker |
International Evaluation of the Aquaporin-4 Antibody Rapid Idot Test
|
| 05:30 PM - 05:36 PM CDT |
Speaker |
High-Throughput Profiling Of Anti-Viral And Self-Antigen Antibodies To Identify Etiology In Encephalitis
|
| 05:36 PM - 05:42 PM CDT |
Speaker |
Results From the Phase 3 X-TOLE2 Study Evaluating Azetukalner, a Novel, Potent KV7 Channel Opener, in Adults With Focal Onset Seizures (FOS)
|
| 05:42 PM - 05:48 PM CDT |
Speaker |
Greater Clinical Benefit with Tiomolibdate Choline Versus Standard-of-care in Neurologic WD Patients in the Phase 3 FoCus Trial
|
| 05:48 PM - 05:54 PM CDT |
Speaker |
Long-Term Risk of Cognitive Impairment with GLP-1 Analogues in Older Adults with Type 2 Diabetes Mellitus
|
| 05:54 PM - 06:15 PM CDT |
Q&A |
Poster Q&A
|